About ATP-sensitive inward rectifier potassium channel 12
ATP-sensitive inward rectifier potassium channel 12 (KCNJ12) is a protein
from Homo sapiens identified by UniProt accession
Q14500, 433 residues long.
MolForge cross-references it against 0 known binders and
83 disease associations.
Target properties
| Protein name | ATP-sensitive inward rectifier potassium channel 12 |
| UniProt accession | Q14500 |
| Gene | KCNJ12 |
| Organism | Homo sapiens |
| Length | 433 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (83)
Diseases linked to this target (Open Targets).
- body height · score 0.45
- body fat percentage · score 0.44
- erythrocyte count · score 0.43
- body mass index · score 0.42
- waist-hip ratio · score 0.39
- mean corpuscular volume · score 0.39
- reticulocyte measurement · score 0.39
- neurodegenerative disease · score 0.38
- appendicular lean mass · score 0.38
- red blood cell density measurement · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q14500-F1 | alphafold | PREDICTED | 80.74 | — |
Amino-acid sequence (433 residues)
MTAASRANPY SIVSSEEDGL HLVTMSGANG FGNGKVHTRR RCRNRFVKKN GQCNIEFANM DEKSQRYLAD MFTTCVDIRW RYMLLIFSLA FLASWLLFGI IFWVIAVAHG DLEPAEGRGR TPCVMQVHGF MAAFLFSIET QTTIGYGLRC VTEECPVAVF MVVAQSIVGC IIDSFMIGAI MAKMARPKKR AQTLLFSHNA VVALRDGKLC LMWRVGNLRK SHIVEAHVRA QLIKPRVTEE GEYIPLDQID IDVGFDKGLD RIFLVSPITI LHEIDEASPL FGISRQDLET DDFEIVVILE GMVEATAMTT QARSSYLANE ILWGHRFEPV LFEEKNQYKI DYSHFHKTYE VPSTPRCSAK DLVENKFLLP SANSFCYENE LAFLSRDEED EADGDQDGRS RDGLSPQARH DFDRLQAGGG VLEQRPYRRE SEI
Explore ATP-sensitive inward rectifier potassium channel 12 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets